NTGN Neon Therapeutics Inc.

1.44
-0.07  -5%
Previous Close 1.51
Open 1.51
Price To Book 0.9
Market Cap 40,714,923
Shares 28,339,196
Volume 307,464
Short Ratio
Av. Daily Volume 415,327
Stock charts supplied by TradingView

NewsSee all news

  1. BioNTech to acquire Neon to strengthen global leadership position in T cell therapies

    Further expands BioNTech's growing CAR-T and TCR therapy pipeline through addition of neoantigen specific cell therapies, including a T cell therapy targeting shared RAS oncogenesAccelerates BioNTech's global expansion

  2. Neon Therapeutics Submits European Clinical Trial Authorization Application for Personal Neoantigen-Targeted T Cell Therapy NEO-PTC-01

    CAMBRIDGE, Mass., Dec. 18, 2019 (GLOBE NEWSWIRE) -- Neon Therapeutics, Inc. (NASDAQ:NTGN) today announced that it has filed a Clinical Trial Authorization (CTA) with the Dutch Health Authority for the evaluation of

  3. Neon Therapeutics Announces New Strategic Focus on Novel T Cell Programs

    Lead program, NEO-PTC-01, is a personalized neoantigen adoptive T cell therapy candidate to address refractory solid tumors Corporate restructuring effected to focus resources while exploring strategic options

  4. Neon Therapeutics Reports Third Quarter 2019 Financial Results and Recent Highlights

    CAMBRIDGE, Mass., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Neon Therapeutics, Inc. (NASDAQ:NTGN), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today reported financial results for the

  5. Neon Therapeutics Announces Publication in Immunity of Novel Approach to Predict MHC Class II Cancer-Specific Neoantigens

    Proprietary class II prediction tool achieved up to a 61-fold improvement in predicting MHC class II peptides compared to standard methods Proprietary capabilities to be integrated into Neon's RECON® bioinformatics

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 1b data due 3Q 2020.
NEO-PV-01 + Keytruda - NT-002
Non-small Cell Lung Cancer (NSCLC)
Phase 1b data released at SITC November 8, 2019.
NEO-PV-01 + nivolumab NT-001
Melanoma, Lung Cancer or Bladder Cancer
Phase 1b future enrolment to be ceased.
NEO-PV-01 and nivolumab - NT-003
Melanoma

Latest News

  1. BioNTech to acquire Neon to strengthen global leadership position in T cell therapies

    Further expands BioNTech's growing CAR-T and TCR therapy pipeline through addition of neoantigen specific cell therapies, including a T cell therapy targeting shared RAS oncogenesAccelerates BioNTech's global expansion

  2. Neon Therapeutics Submits European Clinical Trial Authorization Application for Personal Neoantigen-Targeted T Cell Therapy NEO-PTC-01

    CAMBRIDGE, Mass., Dec. 18, 2019 (GLOBE NEWSWIRE) -- Neon Therapeutics, Inc. (NASDAQ:NTGN) today announced that it has filed a Clinical Trial Authorization (CTA) with the Dutch Health Authority for the evaluation of

  3. Neon Therapeutics Announces New Strategic Focus on Novel T Cell Programs

    Lead program, NEO-PTC-01, is a personalized neoantigen adoptive T cell therapy candidate to address refractory solid tumors Corporate restructuring effected to focus resources while exploring strategic options

  4. Neon Therapeutics Reports Third Quarter 2019 Financial Results and Recent Highlights

    CAMBRIDGE, Mass., Nov. 12, 2019 (GLOBE NEWSWIRE) -- Neon Therapeutics, Inc. (NASDAQ:NTGN), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today reported financial results for the

  5. Neon Therapeutics Announces Publication in Immunity of Novel Approach to Predict MHC Class II Cancer-Specific Neoantigens

    Proprietary class II prediction tool achieved up to a 61-fold improvement in predicting MHC class II peptides compared to standard methods Proprietary capabilities to be integrated into Neon's RECON® bioinformatics